Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of blaOXA-23 on efficacy
- 13 July 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (9) , 2306-2316
Abstract
Objectives: We evaluated the efficacies of human-simulated regimens (HSRs) of two clinically utilized sulbactam regimens: 1 g q6h 0.5 h infusion (maximum FDA-approved dosage) and 3 g q8h 4 h infusion (high-dose, prolonged-infusion regimen), against Acinetobacter baumannii in a translational murine model. Methods: Thirty-two clinical A. baumannii isolates were investigated, of which 16 were sulbactam resistant (MIC ≥ 16 mg/L), 6 were sulbactam intermediate (MIC = 8 mg/L) and 10 were sulbactam susceptible (MIC ≤ 4 mg/L). Efficacies of the two sulbactam HSRs were assessed in the neutropenic murine pneumonia model. Changes in log10 cfu/lungs at 24 h compared with 0 h controls were measured, and efficacy was defined as achieving 1 log kill relative to baseline. WGS of the isolates and bioinformatics analysis were performed to explore potential associations between the genomic backgrounds and the in vivo responses. Results: Eleven isolates harboured blaOXA-23, of which 10 were sulbactam resistant, 1 was sulbactam intermediate while none was sulbactam susceptible. Both sulbactam HSRs achieved >1 log kill against sulbactam-susceptible isolates. Against sulbactam-intermediate and sulbactam-resistant isolates, lack of efficacy correlated with the presence of the blaOXA-23 gene; sulbactam 1 g HSR and 3 g HSR did not show efficacy against 11/11 and 9/11 blaOXA-23-positive isolates, respectively, while efficacy was observed against all 11 blaOXA-23-negative sulbactam-intermediate and sulbactam-resistant isolates (i.e. harbouring other resistance genes). Conclusions: A sulbactam high-dose prolonged-infusion regimen provides comparable activity to the standard dose against isolates currently considered sulbactam susceptible. However, the activity against isolates with intermediate and resistant susceptibility could be predicted by the detection of blaOXA-23. Enhancing detection capabilities of common diagnostic modalities to include OXA-23 can improve patient outcome.Keywords
Funding Information
- US Food and Drug Administration (75F40121C00184)
- Center for Anti-infective Research and Development
- Hartford Hospital
This publication has 25 references indexed in Scilit:
- In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistanceJournal of Global Antimicrobial Resistance, 2022
- Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-ResistantAcinetobacter baumannii, andStenotrophomonas maltophiliaInfectionsClinical Infectious Diseases, 2021
- Rapid detection of OXA-23-like, OXA-24-like, and OXA-58-like carbapenemases from Acinetobacter species by real-time PCRJournal of Hospital Infection, 2020
- OXA-23 and OXA-40 producing carbapenem-resistant Acinetobacter baumannii in Central IllinoisDiagnostic Microbiology and Infectious Disease, 2020
- Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumanniiEuropean Journal of Pharmaceutical Sciences, 2019
- Ampicillin/sulbactam: Its potential use in treating infections in critically ill patientsInternational Journal of Antimicrobial Agents, 2013
- Concordance between physiological arousal and subjective distress among vietnam combat veterans undergoing challenge testing for PTSDJournal of Traumatic Stress, 2012
- Rational antibiotic therapy and the position of ampicillin/sulbactamInternational Journal of Antimicrobial Agents, 2008
- High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumanniiScandinavian Journal of Infectious Diseases, 2007
- Concentrations of ampicillin and sulbactam in serum and in various compartments of the respiratory tract of patientsInfection, 1994